Proactive Investors - Run By Investors For Investors

Admedus signs exclusive distribution agreement in Italy for its unique heart tissue product

According to the World Health Organisation, cardiovascular disease causes more than half of all deaths across Europe.
a human heart
Admedus' bio-scaffold is used to repair congenital heart deformities

Admedus Ltd (ASX:AHZ) has signed an exclusive distribution agreement with Medical Instruments S.p.A. to market and distribute its clinically-superior ADAPT® technology in Italy.

Medical Instruments was founded in 1972 and specialises in the fields of cardiac surgery, vascular surgery, interventional radiology and haemodynamics.

Under the agreement, Medical Instruments will initially distribute Admedus’ non-toxic and non-calcifying flagship ADAPT® bio-scaffold CardioCel®.

The bio-scaffold is used to repair congenital heart deformities and more complex heart defects. It is also used to reconstruct dysfunctional heart valves and valve leaflets.

 

Admedus chief operating officer David St Denis said: “Admedus is delighted to partner with Medical Instruments to distribute our unique, world-leading technology to the patients and surgeons of Italy who have already shown keen interest and adoption of our ADAPT® products.

“According to the World Health Organisation, cardiovascular disease causes more than half of all deaths across Europe, causing 46 times the number of deaths and 11 times the disease burden caused by AIDS, tuberculosis and malaria combined in Europe.”

 

 

St Denis added: “This creates an enormous need, and opportunity, for the type of innovative health solutions and technology that Admedus is focused on delivering.

“Through our partnership with Medical Instruments, who have more than 40 years of demonstrated experience and success in the Italian medical device industry, we anticipate solid growth and development in this key market.”

READ: Admedus progressing towards securing $18 million investment for immunotherapies division

The company is also making progress towards securing a $18 million investment for its immunotherapies business to support ongoing research and development, as well as operational activities.

Admedus recently signed a Memorandum of Understanding (MOU) with Hong Kong investor Star Bright Holding Ltd who has already paid a non-refundable break-fee of $500,000 to finalise the terms of the investment.

View full AHZ profile View Profile

Admedus Ltd Timeline

Newswire
November 01 2018

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
consumer health segment overview
September 17 2018
The company sells clinically validated anti-ageing products for hair, skin and body.
Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use